3
Announcements
Trials
Browse
Landscape
Phase
Phase EARLY_PHASE1
1
Status
Active not recruiting
1
Sponsor Class
OTHER_GOV
1
Study Type
Interventional
1
Sponsor
Cancer Type
Lymphoid
1
Conditions
Carcinoma, Transitional Cell
9
Carcinoma, Merkel Cell
7
Neoplasm Metastasis
6
Breast Neoplasms
6
Urinary Bladder Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
Neoplasms
4
Melanoma
4
Urethral Neoplasms
3
Ureteral Neoplasms
3
Skin Neoplasms
3
Carcinoma, Renal Cell
3
Ovarian Neoplasms
2
Neuroendocrine Tumors
2
Colorectal Neoplasms
2
Carcinoma, Non-Small-Cell Lung
2
Uveal Melanoma
1
Uterine Cervical Neoplasms
1
Turcot syndrome
1
Triple Negative Breast Neoplasms
1
Thymoma
1
Stomach Neoplasms
1
Small Cell Lung Carcinoma
1
Prostatic Neoplasms
1
Primary Myelofibrosis
1
Peritoneal Neoplasms
1
Penile Neoplasms
1
Parkinson Disease 4, Autosomal Dominant Lewy Body
1
Motor Activity
1
Microsatellite Instability
1
Interventions
Rituximab
16
Cyclophosphamide
16
Prednisone
7
Doxorubicin
7
pirtobrutinib
6
fludarabine
6
Vincristine
6
Lenalidomide
6
venetoclax
5
pembrolizumab
5
fludarabine phosphate
5
Etoposide
5
Bendamustine Hydrochloride
5
ibrutinib
4
acalabrutinib
4
Specimen Handling
4
Magnetic Resonance Spectroscopy
4
Dexamethasone
4
CT-P10
4
polatuzumab vedotin
3
etoposide phosphate
3
Immunotherapy, Adoptive
3
tazemetostat
2
liposomal doxorubicin
2
Nivolumab
2
Injections
2
Ifosfamide
2
Gemcitabine
2
Cisplatin
2
Carboplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Lymphoma, B-Cell
×
avelumab
×
Clear all
NCT03244176
2024-07-30
AvR-CHOP
Austin Health
Phase EARLY_PHASE1
Active not recruiting
28 enrolled